Advertisement

Intensive Care Medicine

, Volume 44, Issue 10, pp 1774–1775 | Cite as

Haloperidol serum concentrations in critically ill patients included in the REDUCE study

  • Anne W. van Schijndel
  • Eric J. F. Franssen
  • Peter Pickkers
  • Saskia Rijkenberg
  • Mark van den Boogaard
  • Peter H. J. van der Voort
Letter

Dear Editor,

Introduction

ICU delirium occurs frequently and is associated with unfavorable outcome. A recent delirium prevention study, the REDUCE study, has assessed the efficacy of prophylactic use of haloperidol [1]. This study showed no effect for any group for any outcome [1]. It is unknown if serum levels of haloperidol are related to the effect of haloperidol in prevention or treatment of ICU-acquired delirium. Therapeutic serum levels of haloperidol for treatment of schizophrenia are reported to be 3–20 µg/L [2, 3]. We pre-planned to determine haloperidol serum concentrations in ICU patients receiving prophylactic haloperidol in the REDUCE study.

Methods and results

We included consecutive patients participating in the REDUCE study in one particular ICU. Haloperidol 3 × 1 mg and 3 × 2 mg daily and a placebo group were compared. A blood sample was drawn immediately before the third dose of study medication. This haloperidol trough serum level was assessed by a liquid...

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have any conflict of interest.

References

  1. 1.
    Van den Boogaard M et al (2018) Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial. JAMA 319(7):680–690CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nederlandse Vereniging van Ziekenhuisapothekers (2006) Therapeutic drug monitoring: haloperidol. http://tdm-monografie.org/Media/Default/Monografieen/TDM%20Haloperidol%20210206.pdf. Accessed 23 Aug 2018.
  3. 3.
    Chernecky CC, Berger BJ (2007) Laboratory tests and diagnostic procedures. Elsevier, AmsterdamGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018

Authors and Affiliations

  1. 1.Department of Intensive CareOLVG HospitalAmsterdamThe Netherlands
  2. 2.Department of Clinical PharmacyOLVG Hospital AmsterdamAmsterdamThe Netherlands
  3. 3.Department of Intensive CareRadboud UMC NijmegenNijmegenThe Netherlands

Personalised recommendations